GlassScriptPhysician profile
Mercy George
NPI 1831705524
$4,764.11
in general payments reported to CMS, 2019-2025
34 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,811 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,740 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.07 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $562.54 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Beta Bionics, INC. | $550.85 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $330.18 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $280.12 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $255.08 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $250.68 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $220.30 | 2024-2025 | Strensiq |
| Recordati_rare_diseases_inc. | $212.14 | 2024-2025 | Isturisa, Signifor Lar |
| Averitas Pharma INC. | $200.46 | 2024-2025 | Qutenza |
| Mannkind Corporation | $188.34 | 2024-2025 | |
| Radius Health, INC. | $182.65 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $176.71 | 2024-2025 | Korlym |
| Insulet Corporation | $165.27 | 2024-2025 | Omnipod |
| Novo Nordisk INC | $149.30 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ascendis Pharma Endocrinology INC | $141.66 | 2024-2025 | Yorvipath |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $115.73 | 2025 | |
| Amgen INC. | $103.33 | 2024-2025 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $92.12 | 2024-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $77.84 | 2024-2025 | Unithroid |
| Antares Pharma, INC. | $76.27 | 2024-2025 | Xyosted |
| Almatica Pharma LLC | $71.15 | 2024-2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.86 | 2024-2025 | Jardiance |
| Abbvie INC. | $51.30 | 2024-2025 | |
| Abbott Laboratories | $47.74 | 2025 | Freestyle Libre 3 |
| Soleno Therapeutics, INC. | $28.90 | 2025 | Vykat Xr |
| Cequr Corporation | $25.49 | 2024 | Cequr Simplicity |
| Ibsa Pharma INC. | $24.73 | 2024 | Licart, Tirosint |
| Madrigal Pharmaceuticals | $24.33 | 2024 | Resmetirom |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Tandem Diabetes Care, INC. | $23.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $21.80 | 2024 | NP Thyroid 60 |
| Sequel Med Tech, LLC | $18.66 | 2025 | Twiist |
| Verity Pharmaceuticals INC. | $16.10 | 2025 | Tlando |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2.60 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mercy George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.